Skip to main content
. 2021 Jul 5;12:697180. doi: 10.3389/fmicb.2021.697180

TABLE 4.

Evaluation of the impact of various efflux mutations on potency of QPX7728 (PV50) to enhance antibiotic activity.

Strain1 Genotype/Description Biapenem4 MIC (μg/ml) in the presence of varied concentrations of BLIs (μg/ml)
MIC of the vector only strain (μg/ml) QPX PV505 VAB PV505
alone w/QPX w/VAB (μg/ml) (μg/ml)
PAM4224 Wild-type 64 0.06 4 0.25 1 8
PAM4365 MexA::Tet 64 0.125 0.25 0.25 1 0.5
PAM4126 mexR (MexAB-OprM)2 64 0.125 16 0.125 2 64
PAM4129 nfxB (MexCD-OprJ) 8 0.03 0.25 0.03 0.5 4
PAM4132 mexT (MexEF-OprM)3 128 0.25 32 0.5 1 >64
PAM4150 mexZ (MexXY-OprM) 64 0.25 4 0.25 1 8

1KPC-2 was introduced into isogenic strains of P. aeruginosa containing various efflux mutations and used as a reporter for the QPX7728 BLI activity. 2Mutations in regulatory genes result in overproduction of specific efflux complexes that are shown in brackets. 3The production of a carbapenem porin OprD is reduced by the same mutation in mexT that leads to overproduction of the MexEF-OprN efflux pump. 4Biapenem was chosen as a reporter antibiotic because it’s activity against P. aeruginosa is not affected by efflux. The effect of increasing concentrations of QPX7728 on biapenem MIC against the strains producing KPC-2 in the background of various efflux mutations was determined in a standard checkerboard experiment. 5BLI potency was defined as PV50 (PV stands for potentiation value) which is a concentration of a BLI required to achieve 50% of antibiotic potentiation effect (conceptually equivalent to EC50). It is determined based on the concentration-response curve where antibiotic MICs are plotted vs. BLI concentrations. Data from Lomovskaya et al. (2020a).